Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension
Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials
Marea Therapeutics Secures $190M for Cardiometabolic Medicine Development
Marea Therapeutics, cardiometabolic medicine, clinical-stage program, genetics, ANGPTL4, monoclonal antibody, phase 2 trial, metabolic dysfunction, cardiovascular disease.
Merck’s Capvaxive: FDA Approves First Pneumococcal Vaccine Designed for Adults
Merck, Capvaxive, FDA Approval, Pneumococcal Vaccine, Adults, Pneumonia, Invasive Pneumococcal Disease
Decheng Capital Seeks $700 Million for Fifth Life Sciences Fund Amidst VC Surge
Decheng Capital, Life Sciences Fund, Venture Capital, Biotechnology, Investment Firm
Elion nets $81M to fund development of antifungal with lower toxicity risks
Antifungal Agents, Lower – spatial qualifier, Toxicity aspects, Risk, Elion
Takeda’s Soticlestat Misses Main Goal in Two Pivotal Epilepsy Studies
Soticlestat, Takeda, Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Phase 3 Trials, Seizure Frequency
J&J’s Nipocalimab Shows Promise in Sjögren’s Disease with Significant Phase 2 Results
nipocalimab, Sjögren’s disease, Johnson & Johnson, Phase 2 study, autoimmune disease, FcRn inhibitor
FDA Approves Pembrolizumab and Durvalumab for Endometrial Cancer Treatment
FDA, Pembrolizumab, Durvalumab, Endometrial Cancer, Immunotherapy, Chemotherapy
AstraZeneca’s IMFINZI Plus Chemotherapy Approved in the US for Mismatch Repair Deficient Endometrial Cancer
IMFINZI, durvalumab, endometrial cancer, mismatch repair deficient, chemotherapy, AstraZeneca, FDA approval
Gilead’s Magrolimab Ineffective, Linked to Increased Risk of Death in MDS Patients
Gilead, Magrolimab, MDS, Myelodysplastic Syndrome, Cancer Treatment, Clinical Trials, Safety Concerns